SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals
Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its HANSIZHUANG immunotherapy.
See our latest analysis for Shanghai Henlius Biotech.
These regulatory approvals arrive after a mixed stretch for Shanghai Henlius Biotech’s stock, with the share price up 7.51% year to date but down 11.45% over the past month. The 1-year total shareholder return of...